AR071777A1 - Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos - Google Patents

Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos

Info

Publication number
AR071777A1
AR071777A1 ARP090101723A ARP090101723A AR071777A1 AR 071777 A1 AR071777 A1 AR 071777A1 AR P090101723 A ARP090101723 A AR P090101723A AR P090101723 A ARP090101723 A AR P090101723A AR 071777 A1 AR071777 A1 AR 071777A1
Authority
AR
Argentina
Prior art keywords
polinucleotides
antibodies
pirb
leucocits
immunoglobuline
Prior art date
Application number
ARP090101723A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR071777A1 publication Critical patent/AR071777A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP090101723A 2008-05-13 2009-05-13 Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos AR071777A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration

Publications (1)

Publication Number Publication Date
AR071777A1 true AR071777A1 (es) 2010-07-14

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101723A AR071777A1 (es) 2008-05-13 2009-05-13 Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos

Country Status (15)

Country Link
EP (1) EP2291405A1 (pt)
JP (1) JP2011523359A (pt)
KR (1) KR20110011676A (pt)
CN (1) CN102089327A (pt)
AR (1) AR071777A1 (pt)
AU (1) AU2009246443A1 (pt)
BR (1) BRPI0912769A2 (pt)
CA (1) CA2723430A1 (pt)
IL (1) IL209129A0 (pt)
MX (1) MX2010012299A (pt)
PE (1) PE20091969A1 (pt)
RU (1) RU2010150754A (pt)
TW (1) TW200950808A (pt)
WO (1) WO2009140361A1 (pt)
ZA (1) ZA201007976B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
JP6162219B2 (ja) * 2012-04-17 2017-07-12 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
EP3728318A2 (en) 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
MX2021000009A (es) 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
WO2021222544A1 (en) 2020-05-01 2021-11-04 Ngm Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453540A4 (en) * 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1981522B1 (en) * 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
WO2009140361A1 (en) 2009-11-19
ZA201007976B (en) 2012-02-29
EP2291405A1 (en) 2011-03-09
RU2010150754A (ru) 2012-06-20
KR20110011676A (ko) 2011-02-08
BRPI0912769A2 (pt) 2015-10-13
CA2723430A1 (en) 2009-11-19
CN102089327A (zh) 2011-06-08
JP2011523359A (ja) 2011-08-11
MX2010012299A (es) 2010-12-06
PE20091969A1 (es) 2010-01-15
IL209129A0 (en) 2011-01-31
TW200950808A (en) 2009-12-16
AU2009246443A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AR071777A1 (es) Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
CL2018003821A1 (es) Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo.
UY32449A (es) Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal
CL2014001212A1 (es) Compuestos heterobiciclicos condensados, inhibidores de fosfodiesterasa tipo 10a; composicion farmaceutica que los comprende; y metodo para tratar un trastorno seleccionado entre trastornos neurologicos y trastornos psiquiatricos.
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CO6480999A2 (es) Metodos para aumentar los adipocitos termogenicos
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MX2011012597A (es) Nanoportadores que poseen componentes con diferentes tasas de liberacion.
MX351824B (es) Sistema y método para recompensar a los viajeros diarios.
UY30080A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
PE20210949A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
CR11868A (es) Antagonistas especificos del receptor fgf-r4
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
MX2012001052A (es) Proteccion del cable de fibra optica en un sistema de extraccion.
UY33665A (es) Derivado peptídico
FR2972176B1 (fr) Architectures de freinage hydraulique pour aeronef permettant de freiner au moins une roue de l'aeronef.
ECSP12012023A (es) 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotínicos neuronales de acetilcolina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
AR100978A1 (es) LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal